Achillion Announces Nicole Vitullo Elected to Chair the Board of Directors
January 03 2019 - 6:00AM
Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN), a clinical-stage
biopharmaceutical company dedicated to transforming the lives of
patients and families affected by disorders of the complement
system, today announced that the Company’s Board of Directors has
elected Nicole Vitullo Chair. Ms. Vitullo is a partner with Domain
Associates LLC and has been a member of Achillion's Board of
Directors since September 2010. As Chair, she replaces David
Scheer, who has served on the Achillion Board since 1998 and was
elected Chair in March 2010. Mr. Scheer will remain on the
Board of Directors of the Company.
“Nicole’s successful track record and experience
advising and helping grow public healthcare companies makes her an
excellent choice for this leadership position as we continue to
advance Achillion,” said Mr. Scheer. “We believe Achillion is well
positioned to drive its complement factor D inhibitor programs into
late-stage development and achieve its goal to offer patients new
and innovative treatments for immune-related diseases associated
with the complement alternative pathway.”
Ms. Vitullo, commented, “Achillion is an
exciting clinical stage biopharmaceutical company with a compelling
and promising platform. I am honored to serve as Chair and look
forward to working with David, the other Board members and the
Achillion management team to create both near-term and long-term
value for our shareholders. I would also like to thank David for
his leadership and his significant contributions to Achillion
throughout his tenure.”
Ms. Vitullo serves as a partner at Domain
Associates LLC, a healthcare-focused private equity firm. For more
than a decade, Ms. Vitullo was responsible for Domain Public Equity
Partners L.P., a fund focused on private investments in public
companies. Ms. Vitullo joined Domain Associates in 1999 and became
a Partner in 2004. Prior to Domain, she was senior vice president
at Rothschild Asset Management, Inc. where she had responsibility
for the U.S. public market investments of International
Biotechnology Trust plc and Biotechnology Investments Limited. Ms.
Vitullo currently also serves on the Board of Directors of
Celtaxsys, Esperion Therapeutics, Marinus Pharmaceuticals and
Antios Therapeutics. She received a B.A. in mathematics and an MBA
in finance from the University of Rochester.
About Achillion
PharmaceuticalsAchillion Pharmaceuticals, Inc. (Nasdaq:
ACHN) is a clinical-stage biopharmaceutical
company focused on advancing its oral factor D inhibitors
into late-stage development and commercialization. Factor
D is an essential enzyme in the alternative pathway of the
complement system, a part of the innate immune system. Achillion is
initially focusing its drug development activities on alternative
pathway-mediated diseases where there are no approved therapies or
where existing therapies are inadequate for patients. Potential
indications being evaluated for its compounds include paroxysmal
nocturnal hemoglobinuria (PNH), C3 glomerulopathy (C3G), and immune
complex mediated membranoproliferative glomerulonephritis
(IC-MPGN). Each of the product candidates in the Company’s oral
factor D portfolio was discovered in its laboratories and is wholly
owned. To advance its investigational product candidates into
Phase 3 clinical trials and commercialization, the Company plans to
work closely with key stakeholders including patients, payors,
regulators and healthcare professionals. More information is
available at http://www.achillion.com.
Cautionary Note Regarding
Forward-Looking StatementsThis press release includes
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995 that are subject to risks,
uncertainties and other important factors that could cause actual
results to differ materially from those indicated by such
forward-looking statements. Achillion may use words such as
“expect,” “anticipate,” “project,” “target,” “intend,” “plan,”
“aim,” “believe,” “seek,” “estimate,” “can,” “could” “focus,”
“will,” “look forward,” “continue,” “goal,” “strategy,”
“objective,” “may,” “potential,” and similar expressions to
identify such forward-looking statements. These forward-looking
statements also include statements about: the potential benefits of
factor D inhibition as a treatment for complement-mediated
diseases; the potential benefits of, and indications for,
Achillion’s compounds that inhibit factor D, including ACH-4471,
ACH-5228 and ACH-5548; Achillion’s belief that its portfolio
of compounds could expand factor D portfolio opportunities, provide
strategic optionality or create significant value; Achillion’s
expectations regarding the advancement of, and timeline for
reporting results from, clinical trials of its product candidates
as well as its ability to advance additional compounds; and other
statements concerning Achillion’s strategic goals, efforts, plans,
and prospects. Among the important factors that could cause actual
results to differ materially from those indicated by such
forward-looking statements are risks relating to, among other
things, Achillion’s ability to: demonstrate in any current and
future clinical trials the requisite safety, efficacy and
combinability of its product candidates; advance the preclinical
and clinical development of its complement factor D inhibitors
under the timelines it projects in current and future preclinical
studies and clinical trials; enroll patients in its clinical trials
on its projected timelines; obtain and maintain patent protection
for its product candidates and the freedom to operate under third
party intellectual property; obtain and maintain necessary
regulatory approvals, and the granting of orphan designation does
not alter the standard regulatory requirements and process for
obtaining such approval; establish commercial manufacturing
arrangements; identify, enter into and maintain collaboration and
other commercial agreements with third-parties; compete
successfully in the markets in which it seeks to develop and
commercialize its product candidates and future products; manage
expenses; manage litigation; raise the substantial additional
capital needed to achieve its business objectives; and successfully
execute on its business strategies. These and other risks are
described in the reports filed by Achillion with the U.S.
Securities and Exchange Commission, including its Quarterly Report
on Form 10-Q for the fiscal quarter ended September 30, 2018, and
any other SEC filings that Achillion makes from time to time.
In addition, any forward-looking statement in
this press release represents Achillion's views only as of the date
of this press release and should not be relied upon as representing
its views as of any subsequent date. Achillion disclaims any duty
to update any forward-looking statement, except as required by
applicable law.
Investors & Media:Brian Di
DonatoVice President, Investor Relations and Corporate
CommunicationsAchillion Pharmaceuticals, Inc.Tel. (215)
709-3032bdidonato@achillion.com
Achillion Pharmaceuticals (NASDAQ:ACHN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Achillion Pharmaceuticals (NASDAQ:ACHN)
Historical Stock Chart
From Apr 2023 to Apr 2024